Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

I-Mab

Nasdaq:IMAB
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IMAB
Nasdaq
$742M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders worldwide. The last earnings update was 85 days ago. More info.


Add to Portfolio Compare Print
IMAB Share Price and Events
7 Day Returns
15.6%
NasdaqGM:IMAB
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-
NasdaqGM:IMAB
0%
US Biotechs
-11.5%
US Market
IMAB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
I-Mab (IMAB) 15.6% 4% - - - -
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • No trading data on IMAB.
  • No trading data on IMAB.
Price Volatility
Industry
5yr Volatility vs Market

IMAB Value

 Is I-Mab undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether I-Mab is trading at an attractive price based on the cash flow it is expected to produce in the future. But as I-Mab has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for I-Mab. This is due to cash flow or dividend data being unavailable. The share price is $13.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for I-Mab's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are I-Mab's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:IMAB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in CNY CN¥-396.37
NasdaqGM:IMAB Share Price ** NasdaqGM (2020-03-27) in USD $13
NasdaqGM:IMAB Share Price converted to CNY reporting currency Exchange rate (USD/ CNY) 7.096 CN¥92.25
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of I-Mab.

NasdaqGM:IMAB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:IMAB Share Price ÷ EPS (both in CNY)

= 92.25 ÷ -396.37

-0.23x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • I-Mab is loss making, we can't compare its value to the US Biotechs industry average.
  • I-Mab is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does I-Mab's expected growth come at a high price?
Raw Data
NasdaqGM:IMAB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.23x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
-1.3%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for I-Mab, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on I-Mab's assets?
Raw Data
NasdaqGM:IMAB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in CNY CN¥-520.36
NasdaqGM:IMAB Share Price * NasdaqGM (2020-03-27) in USD $13
NasdaqGM:IMAB Share Price converted to CNY reporting currency Exchange rate (USD/ CNY) 7.096 CN¥92.25
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:IMAB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:IMAB Share Price ÷ Book Value per Share (both in CNY)

= 92.25 ÷ -520.36

-0.18x

* Primary Listing of I-Mab.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • I-Mab has negative assets, we can't compare the value of its assets to the US Biotechs industry average.

Next steps:

  1. Examine I-Mab's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through I-Mab's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess I-Mab's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. I-Mab has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

IMAB Future Performance

 How is I-Mab expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-1.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is I-Mab expected to grow at an attractive rate?
  • Unable to compare I-Mab's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare I-Mab's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • I-Mab's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:IMAB Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:IMAB Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts -1.3%
NasdaqGM:IMAB Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 53.6%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:IMAB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in CNY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:IMAB Future Estimates Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 992 -529 -665 3
2023-12-31 472 -651 -994 3
2022-12-31 322 -621 -922 3
2021-12-31 154 -717 -757 3
2020-12-31 115 -616 -608 3
2020-03-28
2019-12-31 69 -599 -439 2
NasdaqGM:IMAB Past Financials Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income *
2019-09-30 40 -778 -1,227
2019-06-30 47 -606 -1,093
2019-03-31 51 -443 -748
2018-12-31 54 -281 -403
2017-12-31 12 -252 -298

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • I-Mab is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • I-Mab's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:IMAB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from I-Mab Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:IMAB Future Estimates Data
Date (Data in CNY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -10.34 -9.18 -11.49 2.00
2023-12-31 -15.99 -13.93 -18.04 2.00
2022-12-31 -15.41 -12.18 -18.64 2.00
2021-12-31 -13.36 -8.72 -18.01 2.00
2020-12-31 -10.72 -7.98 -13.45 2.00
2020-03-28
2019-12-31 -7.59 -7.59 -7.59 1.00
NasdaqGM:IMAB Past Financials Data
Date (Data in CNY Millions) EPS *
2019-09-30 -396.37
2019-06-30 -363.31
2019-03-31 -255.84
2018-12-31 -141.91
2017-12-31 -119.45

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if I-Mab will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess I-Mab's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
I-Mab has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

IMAB Past Performance

  How has I-Mab performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare I-Mab's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • I-Mab does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare I-Mab's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare I-Mab's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
I-Mab's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from I-Mab Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:IMAB Past Revenue, Cash Flow and Net Income Data
Date (Data in CNY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 40.39 -1,226.85 608.21 689.83
2019-06-30 47.40 -1,093.45 622.29 488.42
2019-03-31 50.59 -748.14 344.34 457.22
2018-12-31 53.78 -402.83 66.39 426.03
2017-12-31 11.56 -298.24 25.44 267.08

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if I-Mab has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if I-Mab has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if I-Mab improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess I-Mab's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
I-Mab has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

IMAB Health

 How is I-Mab's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up I-Mab's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • I-Mab is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • I-Mab's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of I-Mab's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 12.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from I-Mab Company Filings, last reported 5 months ago.

NasdaqGM:IMAB Past Debt and Equity Data
Date (Data in CNY Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 1,290.01 120.33 1,277.48
2019-06-30 1,464.30 117.14 1,269.05
2019-03-31 1,464.30 117.14 1,269.05
2018-12-31 1,960.25 147.03 1,803.85
2017-12-31 716.19 213.01 574.18
  • I-Mab's level of debt (9.3%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if I-Mab's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • I-Mab has sufficient cash runway for 1.6 years based on current free cash flow.
  • I-Mab has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 56.4% each year.
X
Financial health checks
We assess I-Mab's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. I-Mab has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

IMAB Dividends

 What is I-Mab's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from I-Mab dividends.
If you bought $2,000 of I-Mab shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate I-Mab's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate I-Mab's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:IMAB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:IMAB Future Dividends Estimate Data
Date (Data in CN¥) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as I-Mab has not reported any payouts.
  • Unable to verify if I-Mab's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of I-Mab's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as I-Mab has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess I-Mab's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can I-Mab afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. I-Mab has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

IMAB Management

 What is the CEO of I-Mab's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Joan Shen
AGE 56
TENURE AS CEO 0.4 years
CEO Bio

Dr. Joan Huaqiong Shen, M.D., Ph.D., has been Chief Executive Officer of I-Mab since October 2019 and also has been its Director since July 2019. Dr. Shen served as Head of Discovery & Clinical Development at I-Mab since September 2017. She served as the vice president and development head of Janssen Pharmaceutical Companies of Johnson & Johnson from September 2015 to September 2017. Dr. Shen was the chief medical officer and vice president in Jiangsu Hengrui Medicine, Co., Ltd. from May 2013 to August 2015. Dr. Shen served as the head of the China clinical department and a senior director at Pfizer (China) Research and Development Co., Ltd. from August 2011 to May 2013. Prior to that, Dr. Shen worked as a senior medical director at Pfizer Inc. (NYSE: PFE) from November 2009 to August 2011. From August 2005 to November 2009, Dr. Shen was the medical director at Wyeth Research, a leading pharmaceutical company. Dr. Shen worked as a clinical research physician at Eli Lilly and Company (NYSE: LLY) from September 2003 to August 2005. Dr. Shen served as an adjunctive assistant professor in the department of psychiatry of the Indiana University School of Medicine from October 2003 to October 2005. She has also been a guest professor of Beijing University Clinical Research Institute since March 2018. Dr. Shen completed three fellowships in the Indiana University School of Medicine, one in endocrinology from August 1996 to July 1998, one in psychopharmacology and one in clinical pharmacology, both from January 2002 to September 2003. Dr. Shen obtained her U.S. medical license from the Indiana University School of Medicine through a clinical residency. Dr. Shen received her M.D. from Southeast University Medical College in 1983, master’s degree in anatomy from West China University of Medical Sciences, currently Sichuan University School of Medicine in 1989, and her Ph.D. in anatomy/neuroscience from the Indiana University School of Medicine in 1996.

CEO Compensation
  • Insufficient data for Joan to compare compensation growth.
  • Insufficient data for Joan to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the I-Mab management team in years:

2.2
Average Tenure
52
Average Age
  • The tenure for the I-Mab management team is about average.
Management Team

Joan Shen

TITLE
CEO & Director
AGE
56
TENURE
0.4 yrs

Zheru Zhang

TITLE
President & Director
AGE
55
TENURE
2.5 yrs

Jingwu Zang

TITLE
Founder
AGE
62

Jielun Zhu

TITLE
CFO & Director
AGE
42
TENURE
1.6 yrs

Lili Qian

TITLE
Vice President of Operations
AGE
36
TENURE
3.8 yrs

Raven Lin

TITLE
Vice President of Corporate Development
AGE
40
TENURE
2.5 yrs

Weiming Tang

TITLE
Executive Vice President of Global Business Development
AGE
52
TENURE
1.9 yrs
Board of Directors Tenure

Average tenure and age of the I-Mab board of directors in years:

0.7
Average Tenure
55
Average Age
  • The average tenure for the I-Mab board of directors is less than 3 years, this suggests a new board.
Board of Directors

Zheru Zhang

TITLE
President & Director
AGE
55
TENURE
2.5 yrs

Jingwu Zang

TITLE
Founder
AGE
62

Jielun Zhu

TITLE
CFO & Director
AGE
42
TENURE
0.7 yrs

Wei Fu

TITLE
Director
AGE
36
TENURE
1.8 yrs

Joan Shen

TITLE
CEO & Director
AGE
56
TENURE
0.7 yrs

Conor Yang

TITLE
Independent Director
AGE
55
TENURE
0.2 yrs

Mengjiao Jiang

TITLE
Director
TENURE
2.5 yrs

Jie Yu

TITLE
Director
AGE
43
TENURE
0.7 yrs

Lin Li

TITLE
Director
AGE
39
TENURE
1.7 yrs

Howard Weiner

TITLE
Member of Scientific Advisory Board
AGE
74
TENURE
0.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess I-Mab's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. I-Mab has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

IMAB News

Simply Wall St News

IMAB Company Info

Description

I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders worldwide. It is developing TJ202, a CD38 antibody in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; TJ101, a long-acting human growth hormone that is in Phase II clinical trials to treat pediatric growth hormone deficiency; and TJ301, a IL-6 blocker in Phase II clinical trials for the treatment of ulcerative colitis and other autoimmune diseases. The company’s product candidates in Phase I clinical trials include Enoblituzumab, a humanized B7-H3 antibody to treat immuno-oncology; TJ107, a long-acting recombinant human IL-7 to treat cancer treatment-related lymphopenia; TJC4, a CD47 monoclonal antibody with RBC-sparing differentiation; TJD5, a CD73 antibody for immuno-oncology; and TJM2, a GM-CSF monoclonal antibody for rheumatoid arthritis and CAR-T-related therapies. Its product candidates in pre-clinical development comprise TJ210, an antibody targeting myeloid derived suppressor cells in cancers and autoimmune diseases; and TJX7, a novel CXCL13 antibody for autoimmune diseases. The company was founded in 2014 and is headquartered in Shanghai, the People’s Republic of China.

Details
Name: I-Mab
IMAB
Exchange: NasdaqGM
Founded: 2014
$741,788,125
57,060,625
Website: http://www.i-mabbiopharma.com
Address: I-Mab
West Tower, OmniVision,
Suite 802,
Shanghai,
201210,
China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM IMAB SPONSORED ADS Nasdaq Global Market US USD 17. Jan 2020
Number of employees
Current staff
Staff numbers
185
I-Mab employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 03:43
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/17
Last earnings filing: 2020/01/03
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.